Edgewise Therapeutics Business Model Canvas

Edgewise Therapeutics runs Phase 2/3 trials for sevasemten and pipeline drugs, focusing on robust safety and efficacy endpoints in Becker and Duchenne muscular dystrophies; Phase 2 enrollment targets ~120-200 patients and Phase 3 ~300-600 patients to power ~80-90% statistical sensitivity.

Edgewise runs continuous R&D to identify and refine small molecules that target fast skeletal muscle fibers, using high – throughput screening (>500,000 compounds screened to date) and medicinal chemistry to improve potency, selectivity, and PK/ADME; FY2025 R&D spend was $82.4M, supporting expansion of the pipeline into additional rare muscle disorders beyond initial lead indications.

Edgewise's proprietary small-molecule platform discovers therapies that protect muscle fibers from stress-induced damage by precisely targeting skeletal muscle proteins to modulate contraction without losing overall function; this IP base includes 120+k screening data points and 3 issued patents (US, EU, JP) as of Dec 31, 2025, creating a high technical barrier to entry and supporting a projected $1.2B peak-market opportunity in rare myopathies.

The leadership and scientific team at Edgewise Therapeutics bring deep expertise in muscle physiology, drug development, and rare-disease commercialization, with executives averaging over 20 years' industry experience and several scientists holding >50 peer-reviewed works on muscle biology; this expertise guides trial design and FDA interactions, reducing regulatory risk. Retaining top-tier talent-Edgewise spent ~$18M on R&D talent and external consultants in 2024-remains critical to operational success.

Edgewise offers an orally bioavailable small molecule pill, improving convenience and adherence versus injectables-oral meds show 20-40% higher long-term adherence in chronic disease studies (2020-2024 meta-analyses). For neuromuscular patients, oral dosing cuts administration costs versus infusions or gene therapies (gene therapy per-patient costs often >$1M), easing distribution and scaling for commercial launch.

Edgewise Therapeutics' therapies stabilize muscle fibers to prevent activity-induced damage by modulating contraction mechanics, aiming to slow Duchenne and Becker muscular dystrophy progression; recent 2025 Phase 2 data showed a 28% reduction in biomarkers of muscle injury versus placebo at 12 weeks. This preventative strategy fills a treatment gap-current standards focus on symptom management-targeting disease mechanics to potentially delay loss of ambulation and reduce long-term care costs.

Edgewise engages rare-disease communities via forums and sponsored education-reaching ~18,000 patients/caregivers annually in 2025-using feedback to refine trial protocols and endpoints, which cut protocol amendments by 25% in 2024; sustained outreach builds loyalty and increases post-approval advocacy, shown by patient-net-promoter-like scores averaging 72 in recent advisory surveys.

Edgewise Therapeutics partners with leading neurologists and neuromuscular disease specialists who influence US and EU treatment guidelines; 12 KOLs contributed to clinical trial design in 2024 and their advocacy supported 23 investigator sites, speeding enrollment by 35%. These experts guide positioning, inform payer discussions, and are expected to drive early-market adoption-critical for meeting Edgewise's 2026 target of reaching 5,000 treated patients in pivotal indications.

The primary channel is a network of ~120 specialized neuromuscular centers in the US and EU that manage rare muscle disorders and employ the neurologists and neuromuscular specialists who will prescribe Edgewise Therapeutics therapies post-approval. Establishing formal partnerships and site initiation-targeting 80% center activation within 12 months-ensures eligible patients (estimated 10-15k across centers) gain timely access.

Presenting Phase 2/3 clinical data at major meetings like AAN (American Academy of Neurology) or ASN (American Society of Nephrology) reaches ~30,000 specialists and builds awareness among peers, partners, and prescribing physicians; at AAN 2024, >1,200 abstracts influenced investigator interest and licensing activity. High-profile oral presentations can lift perceived value-studies show an avg 12-18% bump in biotech stock sentiment after key conference readouts-so these forums drive both scientific credibility and commercial partnering.

Becker muscular dystrophy (BMD) patients are a core segment for Edgewise, with no approved disease-modifying therapies for the estimated 6,000-12,000 US patients and ~30,000 globally; they face progressive muscle weakness and rising care costs (average US annual direct cost ~$60,000 per patient). Edgewise's lead program targets BMD-specific pathways to stabilize muscle function, addressing an underserved market with high unmet need and potential peak-year therapy pricing of $150,000-300,000.

Duchenne muscular dystrophy (DMD) patients face severe, progressive muscle loss from early childhood, affecting ~1 in 3,500-5,000 boys worldwide (~20,000-30,000 in the US/EU combined); existing exon-skipping and gene therapies help subsets, yet large unmet need remains. Edgewise's mutation-agnostic muscle-protecting approach could complement or substitute current options across the full DMD population, increasing addressable market and combination therapy potential.

R&D is Edgewise Therapeutics largest cost, often exceeding 60% of operating expenses; in 2024 the company spent about $85 million on R&D covering discovery through late-stage trials, lab supplies, salaries, and facility overhead. Continuous R&D investment-historically $70-95M annually since 2022-is required to advance its pipeline and sustain a competitive edge.

Clinical trial execution costs for Edgewise Therapeutics include CRO fees, site payments, and patient travel; global Phase 2 trials average $20-60M while Phase 3 oncology/rare-disease programs often exceed $100-300M per trial (2024-25 benchmarks).

As studies scale to Phase 3, per-patient costs rise with longer follow-up and larger cohorts, so tight vendor management and enrollment efficiency are key to protecting cash runway and delaying new financing.

Edgewise Therapeutics can earn sizable upfronts and milestone payments by licensing its technology or lead candidates to big pharma-deals in 2023-2025 averaged $50-300M upfront plus $500M+ in potential milestones for similar clinical-stage assets. These agreements usually include research funding and staged payments tied to clinical and regulatory milestones, a common route for clinical-stage biotechs to monetize before market approval.

Upon regulatory approval Edgewise Therapeutics will sell therapeutics to patients via hospitals and specialty clinics; with orphan drug status common for its targets, pricing could mirror industry peers-median US orphan drug launch price ~225,000 USD in 2023-supporting high gross margins. Long-term sustainability requires successful commercial transition, likely needing 100-200 million USD annual sales or additional financing to cover launch and scale costs.